WO2009007753A3 - 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer - Google Patents

4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer Download PDF

Info

Publication number
WO2009007753A3
WO2009007753A3 PCT/GB2008/050553 GB2008050553W WO2009007753A3 WO 2009007753 A3 WO2009007753 A3 WO 2009007753A3 GB 2008050553 W GB2008050553 W GB 2008050553W WO 2009007753 A3 WO2009007753 A3 WO 2009007753A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
derivativee
aminopyrazole
pyrimidine
Prior art date
Application number
PCT/GB2008/050553
Other languages
French (fr)
Other versions
WO2009007753A2 (en
Inventor
Huiping Guan
Stephanos Ioannidis
Michelle Lamb
Bo Peng
Mei Su
Tao Wang
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Huiping Guan
Stephanos Ioannidis
Michelle Lamb
Bo Peng
Mei Su
Tao Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Huiping Guan, Stephanos Ioannidis, Michelle Lamb, Bo Peng, Mei Su, Tao Wang filed Critical Astrazeneca Ab
Publication of WO2009007753A2 publication Critical patent/WO2009007753A2/en
Publication of WO2009007753A3 publication Critical patent/WO2009007753A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.
PCT/GB2008/050553 2007-07-11 2008-07-09 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer WO2009007753A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94917107P 2007-07-11 2007-07-11
US60/949,171 2007-07-11

Publications (2)

Publication Number Publication Date
WO2009007753A2 WO2009007753A2 (en) 2009-01-15
WO2009007753A3 true WO2009007753A3 (en) 2009-03-26

Family

ID=40029126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050553 WO2009007753A2 (en) 2007-07-11 2008-07-09 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer

Country Status (1)

Country Link
WO (1) WO2009007753A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
EP2836486B1 (en) * 2012-02-17 2017-10-04 AbbVie Inc. Diaminopyrimidines useful as inhibitors of the human respiratory syncytial virus (rsv)
CA3223058A1 (en) 2021-06-18 2022-12-22 Tongfei Wu Methods and compositions for targeting pd-l1

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038023A1 (en) * 2000-12-21 2005-02-17 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2006115452A1 (en) * 2005-04-27 2006-11-02 Astrazeneca Ab Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038023A1 (en) * 2000-12-21 2005-02-17 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2006115452A1 (en) * 2005-04-27 2006-11-02 Astrazeneca Ab Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
WO2009007753A2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2007049041A8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2009016410A3 (en) Chemical compounds 831
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
WO2008115973A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
MX2009009590A (en) Aminopyrimidines useful as inhibitors of protein kinases.
WO2008137622A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2012017239A3 (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2010120994A3 (en) Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2012066578A3 (en) Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
WO2010042925A3 (en) Compositions and methods for treating alcohol use disorders, pain and other diseases
WO2012162254A8 (en) Inhibitors of lrrk2 kinase activity
MX2013008296A (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors.
WO2010021918A8 (en) Compounds as kinase inhibitors
PL2150530T3 (en) Substituted sulfonamide derivatives
WO2008112651A3 (en) Aminopyrimidines useful as inhibitors of protein kinases
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2007087283A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
MX2009011950A (en) Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors.
MX2010013682A (en) Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders.
MX2009004807A (en) Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08776188

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08776188

Country of ref document: EP

Kind code of ref document: A2